Please assess the completion status of the following clinical trial:

Trial Title: Developmental Regulation of Proteins Responsible for Transforming Drugs in the Body

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: CASE_ONLY
- Primary Purpose: None
- Time Perspective: PROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Healthy children 12 months of age at enrollment~Exclusion Criteria:~* Height and weight ratio outside of the 5th to 100th percentile for adjusted age~* Historical and/or biochemical evidence of hepatic, renal, or hematopoetic dysfunction~* Historical or physical evidence of a neurologic disease/condition (excluding simple, febrile seizures)~* Historical or physical evidence of any disorder associated with swallowing and/or gastrointestinal function~* Concomitant therapy with drugs or other products known to alter the activity of hepatic or intestinal microsomal enzymes(e.g., inducers or inhibitors of CYPs 1A2, 2D6, and/or 3A4), P-glycoprotein or potential competing substrates for the CYPs, under study within 7 days of a scheduled phenotyping evaluation~* Evidence of behavioral, developmental, or psychosocial conditions in the subjects and/or parents/caregivers that, in the opinion of the investigator, would have the potential to adversely impact the level of compliance required for successful study completion~* Evidence of geographic instability (i.e., moving of primary residence within last 24 months) that would adversely influence compliance with repeated study visits necessary for completion of the protocol~* Lack of telephone access required to insure adequate subject contact/follow-up~* Inability to obtain written informed consent from the subject's parents/guardians

- Gender: ALL
- Minimum Age: 12 Months
- Maximum Age: 5 Years
- Healthy Volunteers: t

Based on this trial design, predict the completion outcome and termination type (if applicable).